WO1998013348A1 - Derives de vinylpiridine substitues et medicaments les contenant - Google Patents
Derives de vinylpiridine substitues et medicaments les contenant Download PDFInfo
- Publication number
- WO1998013348A1 WO1998013348A1 PCT/JP1997/003354 JP9703354W WO9813348A1 WO 1998013348 A1 WO1998013348 A1 WO 1998013348A1 JP 9703354 W JP9703354 W JP 9703354W WO 9813348 A1 WO9813348 A1 WO 9813348A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyridyl
- group
- methoxy
- dichloro
- propene
- Prior art date
Links
- 239000003814 drug Chemical class 0.000 title claims abstract description 25
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical class C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title abstract description 8
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 230000006433 tumor necrosis factor production Effects 0.000 claims abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 37
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 150000001204 N-oxides Chemical class 0.000 claims description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 7
- 125000004434 sulfur atom Chemical group 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- 125000002560 nitrile group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
- 125000005081 alkoxyalkoxyalkyl group Chemical group 0.000 claims description 4
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 152
- 230000002401 inhibitory effect Effects 0.000 abstract description 22
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 10
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 6
- 125000003118 aryl group Chemical group 0.000 abstract description 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 5
- 208000027866 inflammatory disease Diseases 0.000 abstract description 5
- 230000003389 potentiating effect Effects 0.000 abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 239000001257 hydrogen Substances 0.000 abstract description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- -1 i-pentyl Chemical group 0.000 description 309
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 94
- 238000002844 melting Methods 0.000 description 64
- 230000008018 melting Effects 0.000 description 64
- 238000006243 chemical reaction Methods 0.000 description 51
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 40
- 125000004432 carbon atom Chemical group C* 0.000 description 40
- 239000000203 mixture Substances 0.000 description 35
- 239000000243 solution Substances 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 31
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000003786 synthesis reaction Methods 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- RMKKUWPWQLCATF-UHFFFAOYSA-N 2-(4-cyclopentyloxy-5-methoxypyridin-2-yl)acetonitrile Chemical compound COC1=CN=C(CC#N)C=C1OC1CCCC1 RMKKUWPWQLCATF-UHFFFAOYSA-N 0.000 description 22
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- 208000006673 asthma Diseases 0.000 description 7
- 229960001701 chloroform Drugs 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- VFADYGMESJXYMK-UHFFFAOYSA-N 2-(4-cyclopentylsulfanyl-5-methoxypyridin-2-yl)acetonitrile Chemical compound COC1=CN=C(CC#N)C=C1SC1CCCC1 VFADYGMESJXYMK-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 150000003333 secondary alcohols Chemical class 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- LLRLGESSNILPSM-UHFFFAOYSA-N 2-(4-cyclopentyloxy-5-ethoxypyridin-2-yl)acetonitrile Chemical compound CCOC1=CN=C(CC#N)C=C1OC1CCCC1 LLRLGESSNILPSM-UHFFFAOYSA-N 0.000 description 4
- UKVQBONVSSLJBB-UHFFFAOYSA-N 2-pyridin-2-ylacetonitrile Chemical compound N#CCC1=CC=CC=N1 UKVQBONVSSLJBB-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000006751 Mitsunobu reaction Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003138 primary alcohols Chemical class 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- ZQRKZHXTOHBMQR-UHFFFAOYSA-N 2-(4-butoxy-5-methoxypyridin-2-yl)acetonitrile Chemical compound CCCCOC1=CC(CC#N)=NC=C1OC ZQRKZHXTOHBMQR-UHFFFAOYSA-N 0.000 description 3
- WCOVVUUVGLPVEV-UHFFFAOYSA-N 2-(4-chloro-5-methoxypyridin-2-yl)acetonitrile Chemical compound COC1=CN=C(CC#N)C=C1Cl WCOVVUUVGLPVEV-UHFFFAOYSA-N 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 3
- 125000005977 3-phenylpropyloxy group Chemical group 0.000 description 3
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 108010003541 Platelet Activating Factor Proteins 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- WOGNFJSCFMIPHD-UHFFFAOYSA-N (4-cyclopentyloxy-5-ethoxypyridin-2-yl)methanol Chemical compound CCOC1=CN=C(CO)C=C1OC1CCCC1 WOGNFJSCFMIPHD-UHFFFAOYSA-N 0.000 description 2
- VJPSGQWODIUGGW-UHFFFAOYSA-N 2-(6-cyclopentyloxy-5-methoxypyridin-2-yl)acetonitrile Chemical compound COC1=CC=C(CC#N)N=C1OC1CCCC1 VJPSGQWODIUGGW-UHFFFAOYSA-N 0.000 description 2
- BLTBFMHWAOQQPE-UHFFFAOYSA-N 2-(chloromethyl)-5-methoxy-4-(2-phenylethoxy)pyridine Chemical compound COC1=CN=C(CCl)C=C1OCCC1=CC=CC=C1 BLTBFMHWAOQQPE-UHFFFAOYSA-N 0.000 description 2
- KSBXDCBRSKRVDC-UHFFFAOYSA-N 2-(chloromethyl)-5-methoxypyridine Chemical compound COC1=CC=C(CCl)N=C1 KSBXDCBRSKRVDC-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- RBFNWOINNIOZKR-UHFFFAOYSA-N 3,5-dichloropyridine-4-carbaldehyde Chemical compound ClC1=CN=CC(Cl)=C1C=O RBFNWOINNIOZKR-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 101150046432 Tril gene Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- BWKVTXSRUFUIJM-UHFFFAOYSA-N [4-(2,3-dihydro-1h-inden-2-yloxy)-5-methoxypyridin-2-yl]methanol Chemical compound COC1=CN=C(CO)C=C1OC1CC2=CC=CC=C2C1 BWKVTXSRUFUIJM-UHFFFAOYSA-N 0.000 description 2
- 150000008360 acrylonitriles Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000010085 airway hyperresponsiveness Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 229940000489 arsenate Drugs 0.000 description 2
- ZZCNKSMCIZCVDR-UHFFFAOYSA-N barium(2+);dioxido(dioxo)manganese Chemical compound [Ba+2].[O-][Mn]([O-])(=O)=O ZZCNKSMCIZCVDR-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- WHFKIZXBVFEJGA-UHFFFAOYSA-L dihydroxy(dioxo)chromium;pyridine Chemical compound O[Cr](O)(=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 WHFKIZXBVFEJGA-UHFFFAOYSA-L 0.000 description 2
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical group N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- XSNUGLQVCGENEM-UHFFFAOYSA-N methyl 3-(cyanomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CC#N)=C1 XSNUGLQVCGENEM-UHFFFAOYSA-N 0.000 description 2
- DSWNRHCOGVRDOE-UHFFFAOYSA-N n,n-dimethylmethanimidamide Chemical compound CN(C)C=N DSWNRHCOGVRDOE-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 125000004344 phenylpropyl group Chemical group 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 2
- MGCGJBXTNWUHQE-UHFFFAOYSA-N quinoline-4-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CC=NC2=C1 MGCGJBXTNWUHQE-UHFFFAOYSA-N 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 229950005741 rolipram Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- JANONUPBHGWOBP-UHFFFAOYSA-N (+-)-3-Carboxyphenylalanine Natural products OC(=O)C(N)CC1=CC=CC(C(O)=O)=C1 JANONUPBHGWOBP-UHFFFAOYSA-N 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- GYPXSIXJCNZMMC-RIYZIHGNSA-N (z)-2-(4-cyclopentyloxy-5-methoxypyridin-2-yl)-3-(3,5-dimethoxypyridin-4-yl)prop-2-enenitrile Chemical compound COC1=CN=C(C(=C\C=2C(=CN=CC=2OC)OC)\C#N)C=C1OC1CCCC1 GYPXSIXJCNZMMC-RIYZIHGNSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- OSAKOAYGMSTAKA-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyridin-2-one Chemical compound OCCN1C=CC=CC1=O OSAKOAYGMSTAKA-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical class C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- KMGCKSAIIHOKCX-UHFFFAOYSA-N 2,3-dihydro-1h-inden-2-ol Chemical compound C1=CC=C2CC(O)CC2=C1 KMGCKSAIIHOKCX-UHFFFAOYSA-N 0.000 description 1
- SPSSULHKWOKEEL-UHFFFAOYSA-N 2,4,6-trinitrotoluene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O SPSSULHKWOKEEL-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- WXSGQHKHUYTJNB-UHFFFAOYSA-N 2,6-dimethoxybenzaldehyde Chemical compound COC1=CC=CC(OC)=C1C=O WXSGQHKHUYTJNB-UHFFFAOYSA-N 0.000 description 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- IWLLXFIRFZABTD-UHFFFAOYSA-N 2-(5-cyclopentyloxy-6-methoxypyridin-3-yl)acetonitrile Chemical compound COC1=NC=C(CC#N)C=C1OC1CCCC1 IWLLXFIRFZABTD-UHFFFAOYSA-N 0.000 description 1
- MBVZUFGDKMXQJS-UHFFFAOYSA-N 2-(oxolan-3-yloxy)pyridine Chemical compound C1OCCC1OC1=CC=CC=N1 MBVZUFGDKMXQJS-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- GGJZWTYNKFMELJ-UHFFFAOYSA-N 2-[5-methoxy-4-(methoxymethoxy)pyridin-2-yl]acetonitrile Chemical compound COCOC1=CC(CC#N)=NC=C1OC GGJZWTYNKFMELJ-UHFFFAOYSA-N 0.000 description 1
- GQBFWVHBFYSEGL-UHFFFAOYSA-N 2-[5-methoxy-4-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]pyridin-2-yl]acetonitrile Chemical compound COC1=CN=C(CC#N)C=C1OCCC1=C(C)N=CS1 GQBFWVHBFYSEGL-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- ZBBMFYOMYYEMJV-UHFFFAOYSA-N 2-cyclopentyloxy-3-methoxy-6-methylpyridine Chemical compound COC1=CC=C(C)N=C1OC1CCCC1 ZBBMFYOMYYEMJV-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- LNUSCVIUFGZNGS-UHFFFAOYSA-N 2-methoxy-1-prop-2-enylnaphthalene Chemical compound C1=CC=CC2=C(CC=C)C(OC)=CC=C21 LNUSCVIUFGZNGS-UHFFFAOYSA-N 0.000 description 1
- YIQGLTKAOHRZOL-UHFFFAOYSA-N 2-methoxynaphthalene-1-carbaldehyde Chemical compound C1=CC=CC2=C(C=O)C(OC)=CC=C21 YIQGLTKAOHRZOL-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- RLFXJQPKMZNLMP-UHFFFAOYSA-N 2-phenylprop-2-enenitrile Chemical compound N#CC(=C)C1=CC=CC=C1 RLFXJQPKMZNLMP-UHFFFAOYSA-N 0.000 description 1
- BXGYBSJAZFGIPX-UHFFFAOYSA-N 2-pyridin-2-ylethanol Chemical compound OCCC1=CC=CC=N1 BXGYBSJAZFGIPX-UHFFFAOYSA-N 0.000 description 1
- OIPHWUPMXHQWLR-UHFFFAOYSA-N 2-pyridin-3-ylacetonitrile Chemical compound N#CCC1=CC=CN=C1 OIPHWUPMXHQWLR-UHFFFAOYSA-N 0.000 description 1
- OKYVYXRJEDLDPS-UHFFFAOYSA-N 2-pyridin-3-ylprop-2-enenitrile Chemical compound N#CC(=C)C1=CC=CN=C1 OKYVYXRJEDLDPS-UHFFFAOYSA-N 0.000 description 1
- BMVSAKPRNWZCPG-UHFFFAOYSA-N 2-pyridin-4-ylacetonitrile Chemical compound N#CCC1=CC=NC=C1 BMVSAKPRNWZCPG-UHFFFAOYSA-N 0.000 description 1
- BBRXCUQHYWVZSF-UHFFFAOYSA-N 2-pyridin-4-ylprop-2-enenitrile Chemical compound N#CC(=C)C1=CC=NC=C1 BBRXCUQHYWVZSF-UHFFFAOYSA-N 0.000 description 1
- RODXBOIDZPQDBH-UHFFFAOYSA-N 3,5-dichloro-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC(Cl)=CC(Cl)=C1 RODXBOIDZPQDBH-UHFFFAOYSA-N 0.000 description 1
- WTVDWWSZNGVKGZ-UHFFFAOYSA-N 3,5-dichloro-1-oxidopyridin-1-ium-4-carbaldehyde Chemical compound [O-][N+]1=CC(Cl)=C(C=O)C(Cl)=C1 WTVDWWSZNGVKGZ-UHFFFAOYSA-N 0.000 description 1
- WPGHPGAUFIJVJF-UHFFFAOYSA-N 3,5-dichloropyridine Chemical compound ClC1=CN=CC(Cl)=C1 WPGHPGAUFIJVJF-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- UHDNUPHSDMOGCR-UHFFFAOYSA-N 3-Formylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C=O)=C1 UHDNUPHSDMOGCR-UHFFFAOYSA-N 0.000 description 1
- JANONUPBHGWOBP-QMMMGPOBSA-N 3-[(2s)-2-amino-2-carboxyethyl]benzoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(C(O)=O)=C1 JANONUPBHGWOBP-QMMMGPOBSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- LDWKAKXKSXBDCZ-UHFFFAOYSA-N 3-methoxy-6-methyl-1h-pyridin-2-one Chemical compound COC1=CC=C(C)N=C1O LDWKAKXKSXBDCZ-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SJLQYVZDSRERTN-UHFFFAOYSA-N 3-prop-1-enylpyridine Chemical compound CC=CC1=CC=CN=C1 SJLQYVZDSRERTN-UHFFFAOYSA-N 0.000 description 1
- ZUGAIMFLQLPTKB-UHFFFAOYSA-N 3-pyridin-3-ylpropan-1-ol Chemical compound OCCCC1=CC=CN=C1 ZUGAIMFLQLPTKB-UHFFFAOYSA-N 0.000 description 1
- LLJRXVHJOJRCSM-UHFFFAOYSA-N 3-pyridin-4-yl-1H-indole Chemical group C=1NC2=CC=CC=C2C=1C1=CC=NC=C1 LLJRXVHJOJRCSM-UHFFFAOYSA-N 0.000 description 1
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical group CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 description 1
- JVYDMMFXFCLVSO-UHFFFAOYSA-N 4-(2,3-dihydro-1h-inden-2-yloxy)-5-methoxypyridine-2-carbaldehyde Chemical compound COC1=CN=C(C=O)C=C1OC1CC2=CC=CC=C2C1 JVYDMMFXFCLVSO-UHFFFAOYSA-N 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- SIJLYRDVTMMSIP-UHFFFAOYSA-N 4-Bromo-1-butanol Chemical compound OCCCCBr SIJLYRDVTMMSIP-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 1
- BVDYOWQBHKPMDZ-UHFFFAOYSA-N 4-cyclopentyloxy-5-methoxypyridine-2-carbaldehyde Chemical compound COC1=CN=C(C=O)C=C1OC1CCCC1 BVDYOWQBHKPMDZ-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- TYDSHPQJCHDHEH-UHFFFAOYSA-N 5-(chloromethyl)-3-cyclopentyloxy-2-methoxypyridine Chemical compound COC1=NC=C(CCl)C=C1OC1CCCC1 TYDSHPQJCHDHEH-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- LABNXKSMAOMDOF-UHFFFAOYSA-N 5-quinolin-2-ylpentan-1-ol Chemical compound C1=CC=CC2=NC(CCCCCO)=CC=C21 LABNXKSMAOMDOF-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- JEAVIRYCMBDJIU-UHFFFAOYSA-N 6-methyl-1h-pyridin-2-one Chemical class CC1=CC=CC(O)=N1 JEAVIRYCMBDJIU-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- JQFPQYBMVDFUEK-UHFFFAOYSA-N ClC=1C=NC=C(C1C=CC#N)Cl Chemical compound ClC=1C=NC=C(C1C=CC#N)Cl JQFPQYBMVDFUEK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- WVDYBOADDMMFIY-UHFFFAOYSA-N Cyclopentanethiol Chemical compound SC1CCCC1 WVDYBOADDMMFIY-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- XOYYFADVMPAZNW-UHFFFAOYSA-N N(=O)O.C=CC Chemical compound N(=O)O.C=CC XOYYFADVMPAZNW-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- URNFIAHZVRABFB-UHFFFAOYSA-N N1(CC=CC=C1)CC#N Chemical compound N1(CC=CC=C1)CC#N URNFIAHZVRABFB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- PBXQJFBDQKMPSX-UHFFFAOYSA-N P(Cl)(Cl)Cl.N1=CC=CC2=CC=CC=C12 Chemical compound P(Cl)(Cl)Cl.N1=CC=CC2=CC=CC=C12 PBXQJFBDQKMPSX-UHFFFAOYSA-N 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- ANUZKYYBDVLEEI-UHFFFAOYSA-N butane;hexane;lithium Chemical compound [Li]CCCC.CCCCCC ANUZKYYBDVLEEI-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 229960002944 cyclofenil Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- UVJHQYIOXKWHFD-UHFFFAOYSA-N cyclohexa-1,4-diene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- MAWOHFOSAIXURX-UHFFFAOYSA-N cyclopentylcyclopentane Chemical group C1CCCC1C1CCCC1 MAWOHFOSAIXURX-UHFFFAOYSA-N 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 125000004990 dihydroxyalkyl group Chemical group 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- IGYRYYXCNGAXIW-UHFFFAOYSA-N ethyl 2-(2-oxopyridin-1-yl)acetate Chemical compound CCOC(=O)CN1C=CC=CC1=O IGYRYYXCNGAXIW-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000004340 exo-2-norbornyl group Chemical group [H]C1([H])C([H])([H])[C@@]2([H])C([H])([H])[C@]1([H])C([H])([H])[C@]2([H])* 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- JBLLRCOZJMVOAE-HSQYWUDLSA-N n-[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methoxy-1h-indole-2-carboxamide Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)C=1NC=2C=CC=C(C=2C=1)OC)C(=O)C=1SC2=CC=CC=C2N=1)[C@@H]1CCNC1=O JBLLRCOZJMVOAE-HSQYWUDLSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 108010028584 nucleotidase Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to a novel substituted vinylpyridine derivative or a salt thereof, which has a potent and selective phosphodiesterase (PDE) IV inhibitory action and a potent tumor necrosis factor (TNF-H) production inhibitory action, and has high safety.
- PDE potent and selective phosphodiesterase
- TNF-H tumor necrosis factor
- PDE has cyclic adenosine 3 ', 5' monophosphate (c AMP) and hydrolyzes cyclic guanosine 3 ', 5'-phosphate (c GMP) to 5'-monophosphate Is an enzyme that acts as a catalyst.
- cAMP and cGMP are generated from ATP and GTP, respectively, and serve as intracellular second messengers.
- the PDE inhibitor has an effect of increasing the intracellular cAMP level and cGMP level by inhibiting PDE activity, thereby suppressing the cellular response.
- PDEs of type I to type VIII are known, and they exist in the central, circulatory, respiratory, digestive, genital, and blood cell systems, etc., but the distribution of these species differs depending on the tissue . This suggests that specific inhibitors of the PDE enzyme may increase cAMP levels in certain tissues.
- PDE IV is eosinophils and eosinophils closely related to asthma pathology. It is distributed mainly in inflammatory cells such as neutrophils and airway tissues.
- PDE V-inhibiting drugs have bronchodilator effects and inflammatory leukocyte activation inhibitory effects. It is thought that it may be effective for both airway inflammation, and PDE IV selective inhibitors are being actively developed worldwide as a new therapeutic agent for bronchial asthma.
- PDE IV is also present in the central nervous system, and the selective inhibitor of PDE IV, rolipram, specifically concentrates in brain tissue and increases the level of cAMP, the second messenger of noruadrenaline.
- cAMP the second messenger of noruadrenaline.
- TNF is a type of cytokine that is produced by activated macrophages, and was discovered as a factor that induces hemorrhagic necrosis at the tumor site, or is now recognized as a mediator widely involved in the inflammatory response and immune system .
- excessive production of TNF-hi causes tissue damage and is a factor leading to various disease states.
- the rapid release of TNF into the serum by the stimulus of bacterial endotoxin and the like can cause shock and even death.
- TNF not only enhances the production of platelet activating factor (PAF), various inflammatory metabolites of rachidonic acid, and active oxygen, but also interleukin (IL ') — and IL-16, IL — 8 to induce production.
- PAF platelet activating factor
- IL ' interleukin
- IL-16 interleukin-16
- IL — 8 interleukin — 8
- TNF-strands can enhance the inflammatory response and maintain a state of comorbidity in chronic inflammatory diseases such as rheumatism, osteoporosis, and terminal stages of cancer, which constantly maintain the levels of these multiple cytokines. It is also a cause of worsening symptoms. Therefore, it is strongly desired from the clinical side to control the release of TNF-hi in a disease state where it is excessively produced.
- Theophylline a xanthine-based drug clinically used for the treatment of bronchial asthma, It exhibits bronchodilator effect based on adenosine antagonism and PDE inhibitory effect, or non-selectively inhibits PDE, and often has cardiovascular and central side effects, resulting in a narrow safety margin.
- Rolipram and Ro 20-1724 selectively inhibit PDE IV at a potency 100 times higher than other PDE isosomes, but the potency is not so strong. Therefore, the adaptation disease is limited.
- TNF-production inhibitors include anti-inflammatory steroids, antihistamines, PAF antagonists, active oxygen scavengers, etc., but these are non-specific inhibitors and have weak or strong titers. However, its tissue specificity is low, and its use is limited. Recently, a protease inhibitor has been reported as a specific inhibitor of TNF-synthesis, but it is a peptide derivative and its administration method has not been sufficiently studied.
- an object of the present invention is to provide a variety of therapeutic drugs based on a selective PDE IV inhibitory action, a variety of therapeutic drugs based on a TNF-production inhibitory action, and a powerful and specific drug based on having both actions.
- Another object of the present invention is to provide a drug for preventing and treating a wide range of inflammatory diseases and autoimmune diseases with high safety.
- the present inventors have synthesized a large number of compounds and studied their PDE inhibitory activity and various cytokine inhibitory activities.
- a novel substituted vinylpyridine represented by the following general formula (1) was obtained. It has been found that a derivative or a salt thereof does not act on other PDE isozymes and potently and selectively inhibits only PDE [V], and also strongly suppresses TNF-production.
- the following substituted vinylpyridine derivatives were shown to be effective for the prevention and treatment of the above-mentioned widespread inflammatory diseases, autoimmune diseases, and diseases related to cerebral apoplexy, thereby completing the present invention.
- R 1 represents a hydrogen atom, an alkyl group, an alkenyl group, an optionally substituted hydroxyalkyl group, an alkoxyalkyl group, an alkoxycarbonylalkyl group, an alkoxyalkoxyalkyl group, or a substituent.
- R 2 represents an alkyl group;
- R 3 and R 4 are different from each other, and one of them represents a hydrogen atom, and the other represents a ditrialkyl group.
- R 5 represents a monocyclic or condensed aryl group which may have a substituent or a monocyclic or condensed aryl group which may have a substituent;
- Heterolysis of condensed rings X represents an oxygen atom or a sulfur atom;
- Q 1 , Q 2, or Q 3 represents a nitrogen atom, and the other two represent CH)
- the present invention also provides a medicament comprising a substituted vinylpyridine derivative represented by the above general formula (1), a salt thereof, a hydrate thereof or an N-oxide thereof as an active ingredient.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a substituted vinylpyridine derivative represented by the above general formula (1), a salt thereof, a hydrate thereof or an N-oxide thereof and a pharmaceutically acceptable carrier. Is what you do.
- the present invention provides the use of a substituted vinylpyridine derivative represented by the above general formula (1), a salt thereof, a hydrate thereof or an N-oxide thereof as a medicament. is there.
- the present invention is characterized in that an effective amount of the substituted vinylpyridine derivative represented by the above-mentioned general formula (1), a salt thereof, a hydrate thereof or an N-oxide thereof is administered to a mammal containing human. It is intended to provide a method for preventing and treating diseases caused by PDEIV or TNF-producing.
- the alkyl group represented by R ′ is a straight-chain, branched-chain, cyclic, cyclic-linear or cyclic having 1 to 12 carbon atoms.
- One-branched alkyl groups are exemplified.
- a linear or branched alkyl group is preferably an alkyl group having 1 to 8 carbon atoms, such as a methyl group, an ethyl group, an n-propyl group, an n-propyl group, an n-butyl group, an i-butyl group, n-pentyl, i-pentyl, n-hexyl, n-heptyl, n-octyl and the like.
- a cycloalkyl group having 3 to 8 carbon atoms is preferable, and examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, and a norbornyl group.
- the cyclic linear or cyclic-branched alkyl group is preferably an alkyl group having 4 to 12 carbon atoms, for example, cyclobutylpyrmethyl group, cyclobutylmethyl group, cyclopentylmethyl group, cyclopropylethyl group, cyclobutylethyl group, cyclopentyl And an ethyl group.
- alkenyl group include a linear, branched or cyclic alkenyl group having 2 to 12 carbon atoms, of which a cyclic alkenyl group having 5 to 8 carbon atoms is more preferable.
- Examples of the cyclic alkenyl group include a 3-cyclopentenyl group, a 2-cyclohexenyl group, a 3-cyclohexenyl group, a 4-cycloheptenyl group, a norbonenyl group, and the like.
- the hydroxyalkyl group may be straight-chain, branched-chain or cyclic, and the number of substituted hydroquine groups may be one or more.
- Hydrokizzi Rukiru S Has preferably 2 to 12 carbon atoms, and particularly preferably 2 to 8 carbon atoms.
- Specific examples of the straight-chain or branched-chain hydroxyalkyl group include 2-hydroxyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl, and 6-hydroxyl. Hexyl group and the like.
- a hydroxycycloalkyl group having 4 to 8 carbon atoms is preferable, and a 3-hydroxycyclobutyl group, a 3-hydroxycyclopentyl group, a 3-hydroxycyclohexyl group, and a 4-hydroxycyclopentyl group are preferred. And a hydroxycyclohexyl group.
- the dihydroxyalkyl group one having 3 to 7 carbon atoms is preferable. For example, 1,3-dihydroxy-2-propyl group, 1,5-dihydroxypentyl group, 1,7-dihydroxyheptyl group, etc. Are mentioned.
- these hydroxyalkyl groups may be substituted with an alkoxycarbonyl group, an acyl group, TBS (t-butyldimethylsilyl group), or the like.
- an alkoxyalkyl group having a total of 2 to 12 carbon atoms is preferable, and examples thereof include a methoxymethyl group, a methoxethyl group, and an ethoxyquinethyl group.
- the alkoxyalkoxyalkyl group is preferably an alkoxyalkoxyalkyl group having a total of 3 to 12 carbon atoms, such as a methoxyethoxyquinmethyl group.
- alkoxycarbonylalkyl group an alkoxycarbonylalkyl group having a total of 3 to 13 carbon atoms is preferable, and examples thereof include a methoxycarbonylmethyl group and an ethoxyquinolponylethyl group.
- the optionally substituted aminoalkyl group examples include a linear or branched aminoalkyl or diaminoalkyl group having 2 to 12 carbon atoms.
- the straight-chain or branched-chain aminoalkyl group preferably has 2 to 8 carbon atoms, for example, 2-aminoethyl group, 3-aminopropyl group, 4-aminobutyl group, 5-aminopentyl group, 6-aminohexyl group and the like.
- the diaminoalkyl group is preferably one having 3 to 7 carbon atoms, for example, 1,3-diamino-2-propyl group, Examples include a 1,5-diaminopentyl group and a 1,7-diaminoheptyl group.
- the amino group may be substituted with an alkoxycarbonyl group, an amino group or the like.
- Examples of the saturated heterocyclic group include a 5- to 6-membered heterocycle having an oxygen atom, a sulfur atom, or a nitrogen atom as a hetero atom.
- Examples thereof include a 2-tetrahydrovillaranyl group, a 3-tetrahydrovillaranyl group, and a 2-tetrahidroxy group.
- Examples include a drofuranyl group and a 3-tetrahydrofuranyl group.
- Examples of the aralkyl group which may have a substituent include a benzyl group, a phenethyl group, a phenylpropyl group, a phenylbutyl group, a plurality of methoxy groups at one or more positions in the 0-, m-, and p-positions; Examples thereof include a benzyl group having an alkoxycarbonyl group or an alkylenedioquine group, a phenyl group and a phenylpropyl group.
- the alkoxy group is preferably an alkoxy group having 1 to 6 carbon atoms, for example, a methoxy group, an ethoxyquin group, n -propoxy group, i-propoxy group and the like.
- the benzocycloalkyl group which may have a substituent is preferably a group having 9 to 11 carbon atoms, for example, 1-indanyl group, 2-indanyl group, 1,2,3,4-tetrahydro-1 1 Mononaphthyl group, and 2,3,4—Tetrahi Draw 2—Nacyl group.
- alkyl group having a heterocyclic ring which may have a substituent examples include an aromatic heterocyclic ring, a saturated heterocyclic ring and an unsaturated heterocyclic ring which are bonded via a linear alkyl group having 1 to 5 carbon atoms.
- aromatic heterocyclic ring examples include a 5- to 6-membered heteroaryl group having 1 to 3 nitrogen, oxygen or sulfur atoms, such as 2-pyridyl, 3-pyridyl and 4-pyridyl.
- 2-pyrimidyl group, 2-virazyl group 2 monothiazolyl group, 5-thiazolyl group, 4-methyl-5-thiazolyl group, 1-imidazolyl group, 2-imidazolyl group, 3-imidazolyl group, 2-oxazolyl group, Examples thereof include a 2-phenyl group, a 3-phenyl group, and a 2-furanyl group.
- a saturated heterocycle or unsaturated heterocycle a nitrogen atom, an oxygen atom or a sulfur atom!
- ⁇ 3 examples thereof include a 5- to 7-membered saturated or unsaturated heterocyclic group, such as 1-pyrrolidyl group, 1-piperidyl group, 1-azepanyl group, 1-morpholino group, pyrrolidin-2-one-1-yl group, pyridine-1 And a 2-one-one-yl group.
- heterocyclic substituents of the benzocycloalkyl group or the heterocyclic aralkyl group include a hydroxyl group, a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, and an i-carbon atom. 1 to 3 selected from 6 halogenoalkyl groups, cyano groups and nitro groups.
- the alkyl group represented by R 2 is preferably an alkyl group having 6 to 6 carbon atoms, for example, a methyl group, an ethyl group, an n-propyl group, an i-propyl group, an n-butyl group, and an i-butyl group. group, sec one butyl group, te 1-t-heptyl c that group, and the like
- an alkoxy group having 1 to 6 carbon atoms is preferable, and examples thereof include a methoxy group, an ethoxyquin group, an n-propoxy group, and an i-propoxy group.
- the monocyclic aryl group which may have a substituent represented by R 5 includes a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, and a halogenoalkyl having 1 to 6 carbon atoms.
- a halogen atom an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, and a halogenoalkyl having 1 to 6 carbon atoms.
- Examples of the condensed aryl group which may have a substituent include a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, and 1 carbon atom.
- a naphthyl group which may be substituted by 1 to 3 groups selected from an alkoxycarbonyl group, a carboxy group, a cyano group and a nitro group, for example, 1-naphthyl group, 2-naphthyl group, 2-chloro- 1-naphthyl group, 2-methoxy 1-naphthyl group and the like.
- Examples of the optionally substituted monocyclic heteroaryl group include a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, and a carbon atom having 1 carbon atom.
- a 5- to 6-membered group having 1 to 3 nitrogen, oxygen or sulfur atoms which may be substituted by 1 to 3 selected from alkoxycarbonyl group, carboxy group, cyano group and nitro group
- Examples include teraryl groups such as 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-hydroxyl-4-pyridyl, 2-methoxycarbonyl-4-pyridyl, and 2-ethoxyquincarbonyl-4 Monopyridyl group, 3-chloro-4-pyridyl group, 3-bromo-4-pyridyl group, 3-methoxy-14-pyridyl group, 3,5-dichloro-14 monopyridyl group, 3,5-dibromo-4 —Pyridyl group, 3, 5 —Dimethoxy— 4 monopyridyl, 3-chloro— 5—Methoxy-4-pyridyl, 2—pyrimidyl, 2—virazyl, 2-phenyl,
- the condensed heteroaryl group which may have a substituent may be a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a halogenoalkyl group having 1 to 6 carbon atoms, or a carbon atom.
- Examples of the salt and hydrate of the substituted vinylpyridine derivative (1) of the present invention include hydrochloride, nitrate, hydrobromide, P-toluenesulfonate, methanesulfonate, fumarate, and maleate. , Malonate, succinate, citrate, tartrate and the like and hydrates thereof.
- Examples of the N-oxide include pyridine-N-oxides of a substituted vinylpyridine derivative. When the substituent represented by R 5 is a monocyclic heteroaryl group or a fused-ring heteroaryl group, N-oxides thereof are also included.
- the process for producing the substituted vinylpyridine derivative of the present invention comprises, for example, a known compound (2) (Step 1) which is easily derived in two or three steps from a large amount of inexpensively available kojic acid as shown in the following scheme. Deriving the key intermediate (3) or (4) in this synthesis method (Step 2 or Step 3), commercially available or separately synthesized aryl aldehydes (R 5 -CHO), aryl acetonitrile, aryl acetic acid It is based on obtaining the compound () a) of the present invention by a dehydration condensation reaction with an ester (R 5 —CH 2 R 7 ).
- R 6 and R 7 are different, one represents a hydrogen atom, the other represents a nitrile group or an alkoxycarbonyl group, Y represents a hydrogen atom or a protecting group, and a preferable protecting group is benzyl or tetrahydro 2 Biraniru group ⁇ up is, R 2 and R 5 are as defined above, R ia except a hydrogen atom, exhibit the same meaning as R ', arsenate mud Kin alkyl In the case of a group, the presence of a protecting group is preferred.) That is, the key intermediate (3) is reacted with R 5 — CH ⁇ (step 4), and the key intermediate (4) is reacted with R 5 — CH 2 R 7 (step 5) to obtain the compound (1).
- a) can be obtained.
- This reaction proceeds easily in the presence of a base such as sodium alkoxide, sodium amide ', alkali hydroxide, alkyllithium, tertiary alkylamine, or the ability to use sodium methkind in a methanol solvent, ethanol
- a base such as sodium alkoxide, sodium amide ', alkali hydroxide, alkyllithium, tertiary alkylamine, or the ability to use sodium methkind in a methanol solvent, ethanol
- the reaction is preferably performed at 0 ° C. to room temperature using sodium methoxide in a solvent.
- the key intermediate (3) can be easily obtained from the known compound (2) by the method shown in the following scheme.
- R le , R 2 and Y have the same meaning as described above, and Z represents a leaving group represented by a halogen atom.
- the reaction in step 2a is carried out in a solvent such as alcohol, tetrahydrofuran, dimethylformamide, or dimethylsulfoxide, in the presence of a base such as potassium carbonate or sodium carbonate, and, in some cases, in the presence of iodium iodium or sodium iodide, at room temperature.
- a solvent such as alcohol, tetrahydrofuran, dimethylformamide, or dimethylsulfoxide
- a base such as potassium carbonate or sodium carbonate
- iodium iodium or sodium iodide at room temperature.
- the reaction is carried out at a temperature of from 0 ° C. to 80 ° C. or a reflux temperature of 0 ° C. using sodium hydroxide or potassium hydroxide as a base in a mixed solvent of water and alcohol.
- the substituent for R la is preferably an alkyl group, a cycloalkyl group, a cycloalkylalkyl group, a hydroquinalkyl group, or an optionally substituted aralkyl group.
- Y protecting group
- a cycloalkyl group, a cycloalkenyl group, a heterocycloalkyl group, or a benzocycloalkyl group is preferred.
- a tetrahydro-2-biranyl group-substituted product hydrolysis conditions using a mineral acid or an organic acid in a water-organic solvent are used.
- the thionyl chloride and the compound (5) are used without solvent or inactive to the thionyl chloride. It is easily performed at room temperature in a suitable solvent.
- the reaction for obtaining the key intermediate (3: R 6 nitrile group) from the chloro form (6) is carried out by using sodium cyanide in a polar aprotic solvent such as dimethyl sulfoxide or dimethylformamide at room temperature.
- the reaction is preferably carried out at a temperature of from 100 to 100, but can also be easily carried out by a cyanoaione activation method using a phase transfer catalyst or a crown ether.
- the key intermediate Convert the nitrile group of (3 R 6 Ninitoriru group), a key intermediate: In the reaction for obtaining a (3 R 6 two alkoxycarbonyl group), hydrogen chloride gas saturated methanol or a lower alcohol, at room temperature To the reflux temperature to obtain the corresponding alkoxycarbonyl compound.
- the key intermediate (4) can be easily obtained from the known compound (2) by using any of the steps shown in the following scheme.
- Step 2 a / " ⁇ Step 3 b
- step 3b the compound (5) obtained in the above step 2a is converted into a formyl compound (4) by an oxidizing agent.
- step 3b the compound (2) is oxidized to a compound (7) (In step 3a), a compound (7) is reacted with various halide reagents (R la —Z) to obtain a formyl compound (4) (step 3c).
- the reaction for obtaining compound (7) from compound (2) (step 3a) is excessive as an oxidizing agent.
- the reaction is preferably carried out at room temperature to 100 ° C. in a solvent such as tetrahydrofuran, 1,4-dioxane or dimethylformamide using an amount of active manganese dioxide or barium manganate (IV).
- the reaction for obtaining the formyl compound (4) from the compound (5) is carried out by using an excess amount of active manganese dioxide or barium manganate (VI) as an oxidizing agent in a solvent such as chloroform, dichloromethane or acetone. It can be easily carried out from room temperature to reflux temperature, or by oxidation with dimethyl sulfoxide / sulfur trioxide-pyridine complex (Parikh-Doenng method), or with dimethyl sulfoxide Z oxalyl chloride (Swern method).
- the formyl compound (4) can also be obtained by using an oxidation reaction with pyridinium chromate (PCC) or pyridinium dichromate (PDC).
- the reaction for obtaining the formyl compound (4) from the compound (7) (step 3c) is carried out using sodium hydride, potassium hydride or the like as a base, tetrahydrofuran, 1,2-dimethyloxetane, dimethylformamide, dimethyl in a solvent such as sulfoxides, 0 ° C from room temperature R la - force ,, alcohol to be reacted with Z, tetrahydrofuran, di-methyl formamidine de, in a solvent such as dimethyl sulfoxide, potassium carbonate, basic carbonate and the like Na Bok Riumu and In some cases, the reaction is carried out at 0 to 80 ° C in the presence of potassium iodide, sodium iodide, or the like.
- R ' has a main Tokishimechiru group or main Tokishe Tokishimechiru group, having a hydrogen atom at R 7 (1 a'), or to have a hydrogen atom (1 a
- the compounds of the present invention (1b ') and (1b ") can be obtained by removing the oxyalkyl group of ⁇ ).
- R 'of compounds (1a') and (1a ') is a methoxymethyl group
- R' is a methoxetoxymethyl group use trifluoroacetic acid. Can be deprotected.
- This hydrolysis reaction is carried out under low-temperature conditions by using dilute sodium hydroxide or potassium hydroxide aqueous solution in a lower alcohol, which is the most widely used method, at room temperature to reflux temperature.
- (La) can also be obtained by the Mitsunobu reaction of (1b ') or (1b ⁇ ) with various primary or secondary alcohols (R-OH).
- this substituent introduction reaction using various halide reagents is carried out in a solvent such as alcohol, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, etc., in a solvent such as potassium carbonate, sodium carbonate, etc. Perform at room temperature to 80 ° C in the presence of potassium iodide, sodium iodide, etc., or use tetrahydrofuran,
- the compound (1d) having a sulfur atom at X can be derived from the compound (2 ′) by the method shown in the following scheme.
- R ′ 6 , R 2 and R 5 have the same meaning as described above, and M represents an alkali metal.
- the reaction for obtaining (1d) proceeds under the same conditions as described above.
- the reaction for obtaining the di- ⁇ -open body (8) from the compound (2 ') is carried out by heating and refluxing in phosphorus oxychloride.
- an alcohol is used in the reaction for obtaining the key intermediate (10) from the compound (9). It is preferably carried out at room temperature to 80 ° C. in a solvent such as tetrahydrofuran, dimethylformamide or dimethylsulfoxide in the presence of a base such as potassium carbonate or sodium carbonate.
- 6-alkoxy-15-hydroxy-13-pyridinemethanols compounds in which Q 3 is N
- 5-alkoxy- are substituted for the compounds of the formulas (2) and (2 ′) as starting materials.
- the same reaction is carried out using 6-hydroxy-2-picolines (a compound in which Q 2 is N) to produce a compound of the general formula (wherein Q 2 or Q 3 is a nitrogen atom). Can be.
- the reaction mixture present invention compound (1) to isolate a conventional method, such as solvent extraction, recrystallization, settle for by utilizing a means such as column chromatography, the present invention obtained in c thus
- the compound has a selective and potent PDE [V inhibitory activity and a TNF-proliferative inhibitory activity, and is useful as a PDE IV inhibitor, a TNF-proliferative inhibitor, and a PDE IV and / or TNF-proliferative inhibitor.
- the medicament of the present invention includes, for example, immediate-type, late-type asthma represented by bronchial asthma, allergy due to inhibition of activation of inflammatory blood cells such as airway hyperresponsiveness or eosinophils, atopy, rheumatism, etc.
- inflammatory blood cells such as airway hyperresponsiveness or eosinophils, atopy, rheumatism, etc.
- Prevention and treatment of autoimmune diseases depression related to cerebral metabolic disorders, cerebral infarction, senile dementia, Parkinson's disease, drugs for treatment, osteoporosis, type I and type II diabetes, inflammation, cancer, HIV infection, AI It is useful as a preventive and remedy for DS and bacterial endotoxin-induced shock.
- the compound of the present invention can be converted into tablets, granules, powders, capsules, inhalants, suspensions, injections, suppositories, external preparations and other various forms of pharmaceutical preparations in a usual manner.
- a compound, a binder, a disintegrant, a bulking agent, a coating agent, a sugar-coating agent and the like are added to the compound of the present invention, and then tablets and granules are prepared in a conventional manner.
- Capsules, Suppositories are preferred.
- the compound of the present invention When preparing an injection, the compound of the present invention may be previously dissolved, dispersed, emulsified, or the like in an aqueous carrier such as distilled water for injection, or may be made into a powder for injection and dissolved at the time of use.
- Injection administration methods include intravenous administration, intraarterial administration, intraperitoneal administration, subcutaneous administration, and intravenous infusion.
- the dose varies depending on the administration method, the age, weight, and condition of the patient, or 5 to 5 times a day when administered orally to adult patients.
- it is 10 Omg.
- reaction solution was poured into a 5% aqueous solution of ammonium chloride 100 and extracted with ethyl acetate.
- the extract was washed sequentially with water and saturated saline, dried, and evaporated under reduced pressure.
- the residue was purified by silica gel column chromatography ⁇ to obtain 27.2 g (yield 77%) of the title compound.
- N- eth Kin carbonylmethyl - dissolving 2-pyridone 3. 62 g of (20mmo) di O-hexane 1 0, a 9 0% L i BH 4 0. 9 6 g (4 0 mmo) was added, 20 minutes Heated to reflux. Next, add 207 ⁇ ethyl acetate, heat to reflux for 5 minutes, and react. The liquid was dried under reduced pressure. Water was added to the residue, and the mixture was extracted three times with chloroform. After drying, the residue was distilled off under reduced pressure. The residue was purified by silica gel column chromatography to obtain 1.15 g (yield: 41%) of the title compound.
- 6-cyclopentyloxy-5-methoxy-2—pyridineacetonitrile 6-Hydroxy-5-methoxy-2-picoline and bromocyclopentane were used. In the same manner as in Production Example 1, 6-cyclopentyloxy-5-methoxy-12-picoline was obtained.
- 6-cyclopentyloxy-5-methoxy-2-picoline 0.83 g (4.0 ⁇ 0 and N-bromosuccinic acid imide 0.80 g (4.4 strokes 0 to 10 m carbon tetrachloride
- the mixture was dissolved, a catalytic amount of benzoyl peroxide was added, and the mixture was heated under reflux for 2 hours.After cooling, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate.The organic layer was washed with water, dried, and evaporated under reduced pressure. The product was used for the next reaction as it was.
- Example 4 The following compounds were obtained in the same manner as in Example 1 below, using 4-cyclopentyloxy-5-methoxy-2-pyridinacetonitrile (3a) and 4-pyridinepyridinecarbaldehyde. .
- Example 7 The same procedures as in Example 1 were carried out using 4-butyroxy-5-methoxy-2-pyridinacetonitrile (3e) and 3,5-dichloro mouth-4-pyridinecarbaldehyde (Production Example 7). The following compounds were obtained by the method.
- Example 7 The same procedure as in Example 1 was conducted using 4-cyclopentyloxy-5-ethoxy-2-pyridinacetonitrile (3d) and 3,5-dichloro-4-pyridinecarbaldehyde (Production Example 7). The following compounds were obtained by the method described above.
- reaction solution was evaporated to dryness under reduced pressure, water was added to the residue to dissolve it, and a saturated sodium hydrogen carbonate solution was added to adjust the pH to about pH 6.
- the precipitated crystals are collected by filtration, washed with water and recrystallized from ethanol. This gave 0.56 g (88% yield) of the title compound.
- reaction solution was evaporated to dryness under reduced pressure, water was added to the residue, and the mixture was extracted with ethyl acetate. The extract was washed with saturated saline, dried, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography, and recrystallized from a mixture of benzene and hexane to obtain 24 Omg (yield: 59%) of the title compound.
- Test example 1 PDE inhibitory activity test
- PDE activity was measured by the two-step Atssey-like method of Hidaka et al. (Bioph. Bioch. Acta. (1976), 429, p485). '
- the diluted solution of the enzyme contains 5 Om Tr 1 s -HC 1 (pH 8.0), 5 (m ⁇ l MgCl 2 and 50 g of bovine serum albumin as final concentration.
- the substrate concentration is I / Containing 0.1 to 100% of the test compound, incubated at 30 ° C for 20 minutes, and the PDE reaction is stopped by boiling for 2 minutes.
- For the reotidase reaction add snake venom nucleotidase to the above reaction mixture and incubate at 30 ° C for 20 minutes.
- Test compound IC 5 The values were determined from the concentration-response curves at concentrations ranging from 0.1 to 100.
- Test example 2 TNF- ⁇ production inhibition test
- coli, 0111: 84 was added. Each compound was added 1 hour before LPS treatment to give 100, 100, 1 and 0.iM concentrations. Added. Furthermore, 6 hours after the addition of LPS, the amount of TNF- produced in the supernatant was measured using a human TNF-aEL ISA kit (Amersham, code RPN 2758). Assuming that the amount of TNF- was 100%, ⁇ control was calculated for each dose of each compound. Further, IC 5 of the inhibitory activity of NF-production for each compound from the linear regression line. Values were calculated.
- a tablet having the above composition was produced by a conventional method. These tablets can be made into sugar-coated tablets and film-coated tablets, if necessary.
- Formulation Example 2 Capsules
- Glucose 5 Omg Distilled water for injection qs Total 1 m The injection having the above composition was produced by a conventional method.
- An intravenous infusion having the above composition was produced by a conventional method.
- the 2-substituted vinylpyridine derivative of the present invention has a potent and selective PD ⁇ V inhibitory action and a strong TNF-production inhibitory action.
- drugs based on selective PDE IV inhibitory action can be used for a variety of diseases, such as immediate, late asthma, collectively referred to as bronchial asthma, airway hyperresponsiveness, or inhibition of the activation of inflammatory blood cells such as eosinophils. It is useful for the prevention and treatment of autoimmune diseases such as allergies, atopy and rheumatism, depression related to cerebral metabolic disorders, cerebral infarction, senile dementia, and memory impairment associated with Parkinson's disease.
- TNF-production inhibitory activity can be used for the prevention and treatment of various diseases such as rheumatism, osteoporosis, type I and type II diabetes, cancer, HIV infection, AIDS, and shock caused by bacterial endotoxin. Useful.
- the compound of the present invention has a selective PDE [V inhibitory action and a TNF- It is useful for prevention and treatment of more inflammatory diseases and autoimmune diseases.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69727915T DE69727915T2 (de) | 1996-09-25 | 1997-09-22 | Substituierte vinylpyridinderivate und arzneimittel, die diese enthalten |
EP97940447A EP0882714B1 (en) | 1996-09-25 | 1997-09-22 | Substituted vinylpyridine derivatives and drugs containing the same |
US09/068,986 US5935977A (en) | 1996-09-25 | 1997-09-22 | Substituted vinyl pyridine derivative and drugs containing the same |
KR1019980703387A KR100517452B1 (ko) | 1996-09-25 | 1997-09-22 | 치환 비닐피리딘 유도체 및 이를 함유하는 의약 |
CA002236851A CA2236851C (en) | 1996-09-25 | 1997-09-22 | Substituted vinylpyridine derivatives and drugs containing the same |
AT97940447T ATE260898T1 (de) | 1996-09-25 | 1997-09-22 | Substituierte vinylpyridinderivate und arzneimittel, die diese enthalten |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8/252944 | 1996-09-25 | ||
JP25294496 | 1996-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998013348A1 true WO1998013348A1 (fr) | 1998-04-02 |
Family
ID=17244339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/003354 WO1998013348A1 (fr) | 1996-09-25 | 1997-09-22 | Derives de vinylpiridine substitues et medicaments les contenant |
Country Status (9)
Country | Link |
---|---|
US (1) | US5935977A (ja) |
EP (1) | EP0882714B1 (ja) |
KR (1) | KR100517452B1 (ja) |
CN (1) | CN1169792C (ja) |
AT (1) | ATE260898T1 (ja) |
DE (1) | DE69727915T2 (ja) |
ES (1) | ES2217428T3 (ja) |
TW (1) | TW517056B (ja) |
WO (1) | WO1998013348A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005115996A1 (en) | 2004-05-24 | 2005-12-08 | Sterix Limited | Sulfamic acid ester compounds useful in the inhibition of seroid sulphatase activity and aromatase activity |
WO2008096155A1 (en) | 2007-02-08 | 2008-08-14 | Sterix Limited | Composition comprising a glycolytic inhibitor and a ring system comprising a sulphamate group for the treatment of cancer |
EP2202240A1 (en) | 2000-08-18 | 2010-06-30 | Sterix Limited | Compound |
WO2011023989A1 (en) | 2009-08-24 | 2011-03-03 | Sterix Limited | Aromatase inhibitor |
US8119627B2 (en) | 2005-07-04 | 2012-02-21 | Sterix Limited | Heterocyclic compounds as inhibitors of 17beta-HSD3 |
US8394825B2 (en) | 2007-03-28 | 2013-03-12 | Sterix Limited | Compound |
US8470860B2 (en) | 2004-06-04 | 2013-06-25 | Sterix Limited | Phenyl-sulfamates as aromatase inhibitors |
US8558028B2 (en) | 2007-11-20 | 2013-10-15 | University Of Bath Of Claverton Down | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE218549T1 (de) * | 1993-07-28 | 2002-06-15 | Aventis Pharma Ltd | Verbindungen als pde iv und tnf inhibitoren |
US6368815B1 (en) | 1999-03-29 | 2002-04-09 | Warner-Lambert Company | Screening of molecules that inhibit human phosphodiesterase 4A produced by non-recombinant cell lines |
WO2001030757A1 (fr) * | 1999-10-28 | 2001-05-03 | Microcide Pharmaceuticals, Inc. | Inhibiteurs de la pompe par liberation de medicaments |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US7056917B2 (en) * | 2001-04-26 | 2006-06-06 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
WO2002087589A1 (fr) * | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Medicament permettant d'inhiber une pompe d'elimination de medicament |
ATE464068T1 (de) | 2001-06-26 | 2010-04-15 | Amgen Fremont Inc | Antikörper gegen opgl |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
AU2003236340A1 (en) * | 2002-04-02 | 2003-10-27 | Tsumura & Co. | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative |
EP1578782A4 (en) | 2002-12-30 | 2007-09-12 | Amgen Inc | COSTIMULATING FACTORIAL THERAPY |
JP4621198B2 (ja) * | 2003-02-11 | 2011-01-26 | プロシディオン・リミテッド | トリ(シクロ)置換アミドグルコキナーゼ活性化化合物 |
KR101599804B1 (ko) * | 2012-08-28 | 2016-03-04 | (주)로커스 | 관 삽입 확인장치 및 관을 대상물에 연결시키는 방법 |
WO2014083106A1 (en) * | 2012-11-28 | 2014-06-05 | Sanofi | Process for preparing 4-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0157420A2 (en) * | 1984-04-04 | 1985-10-09 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient |
WO1997033870A1 (fr) * | 1996-03-15 | 1997-09-18 | Ss Pharmaceutical Co., Ltd. | Nouveaux derives de pyridine et medicaments contenant ces derives en qualite d'ingredient actif |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9401460D0 (en) * | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
-
1997
- 1997-09-22 AT AT97940447T patent/ATE260898T1/de not_active IP Right Cessation
- 1997-09-22 CN CNB971914923A patent/CN1169792C/zh not_active Expired - Fee Related
- 1997-09-22 KR KR1019980703387A patent/KR100517452B1/ko not_active IP Right Cessation
- 1997-09-22 WO PCT/JP1997/003354 patent/WO1998013348A1/ja active IP Right Grant
- 1997-09-22 DE DE69727915T patent/DE69727915T2/de not_active Expired - Fee Related
- 1997-09-22 US US09/068,986 patent/US5935977A/en not_active Expired - Lifetime
- 1997-09-22 EP EP97940447A patent/EP0882714B1/en not_active Expired - Lifetime
- 1997-09-22 ES ES97940447T patent/ES2217428T3/es not_active Expired - Lifetime
- 1997-09-24 TW TW086113884A patent/TW517056B/zh not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0157420A2 (en) * | 1984-04-04 | 1985-10-09 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient |
WO1997033870A1 (fr) * | 1996-03-15 | 1997-09-18 | Ss Pharmaceutical Co., Ltd. | Nouveaux derives de pyridine et medicaments contenant ces derives en qualite d'ingredient actif |
Non-Patent Citations (2)
Title |
---|
CIRC. SHOCK., Vol. 44, No. 3, LEE J.C., PRABHAKAR U., GRISWOLD D.E., DUNNINGTON D., YOUNG P.R., BADGER A., "Low-Molecular-Weight TNF Biosynthesis Inhibitors: Strategies and Prospectives", pages 97-103. * |
CURR. PHARM. DES., Vol. 1, No. 2, LOBARDO L.J., "Phosphodiesterase-IV Inhibitors: Novel Therapeutics, for the Treatment of Inflammatory Diseases", pages 255-268. * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2202240A1 (en) | 2000-08-18 | 2010-06-30 | Sterix Limited | Compound |
WO2005115996A1 (en) | 2004-05-24 | 2005-12-08 | Sterix Limited | Sulfamic acid ester compounds useful in the inhibition of seroid sulphatase activity and aromatase activity |
US8470860B2 (en) | 2004-06-04 | 2013-06-25 | Sterix Limited | Phenyl-sulfamates as aromatase inhibitors |
US8119627B2 (en) | 2005-07-04 | 2012-02-21 | Sterix Limited | Heterocyclic compounds as inhibitors of 17beta-HSD3 |
WO2008096155A1 (en) | 2007-02-08 | 2008-08-14 | Sterix Limited | Composition comprising a glycolytic inhibitor and a ring system comprising a sulphamate group for the treatment of cancer |
US8394825B2 (en) | 2007-03-28 | 2013-03-12 | Sterix Limited | Compound |
US8558028B2 (en) | 2007-11-20 | 2013-10-15 | University Of Bath Of Claverton Down | Compound capable of inhibiting 17-beta hydroxysteriod dehydrogenase |
WO2011023989A1 (en) | 2009-08-24 | 2011-03-03 | Sterix Limited | Aromatase inhibitor |
US8846737B2 (en) | 2009-08-24 | 2014-09-30 | Sterix Limited | Compound |
Also Published As
Publication number | Publication date |
---|---|
CN1206407A (zh) | 1999-01-27 |
CN1169792C (zh) | 2004-10-06 |
EP0882714A1 (en) | 1998-12-09 |
EP0882714A4 (en) | 2000-02-09 |
ATE260898T1 (de) | 2004-03-15 |
KR100517452B1 (ko) | 2007-03-15 |
US5935977A (en) | 1999-08-10 |
KR19990067377A (ko) | 1999-08-16 |
TW517056B (en) | 2003-01-11 |
DE69727915T2 (de) | 2004-08-19 |
DE69727915D1 (de) | 2004-04-08 |
EP0882714B1 (en) | 2004-03-03 |
ES2217428T3 (es) | 2004-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998013348A1 (fr) | Derives de vinylpiridine substitues et medicaments les contenant | |
JP4875623B2 (ja) | 壊死又はアポトーシスによって生じた組織損傷又は疾患の治療におけるポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としての3,6−置換された5−アリールアミノ−1h−ピリジン−2−オン誘導体及び関連化合物 | |
JP5837573B2 (ja) | ピコリンアミド及びピリミジン‐4‐カルボキサミド化合物、その製造方法及びそれを含む医薬組成物 | |
TWI292318B (en) | Imidazol-4-yl-ethynyl-pyridine derivatives | |
CN101184734B (zh) | 治疗细胞增殖紊乱的化合物和方法 | |
AU2003225964B2 (en) | Substituted 2,3-diphenyl pyridines | |
US7902229B2 (en) | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | |
CN101595084B (zh) | 用于调整激酶级联的二芳基组合物和方法 | |
CA2746307C (en) | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | |
TW200306180A (en) | New compounds | |
TW200825062A (en) | Biaryl ether urea compounds | |
US20060160861A1 (en) | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | |
TW200524901A (en) | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | |
TW201038554A (en) | Nicotinamide derivatives, their preparation and their therapeutic application | |
US20060128757A1 (en) | Pyridine derivatives useful as cyclooxygenase inhibitor | |
AU2021368547A1 (en) | Compound, aldehyde dehydrogenase 2 activating agent, pharmaceutical composition, and therapeutic and/or prophylactic drug | |
KR20200078591A (ko) | 키나제 억제제로서의 아미노이미다조피리다진 | |
KR20070085609A (ko) | 혈관 내피 성장 인자 (vegf) 수용체 키나제 억제제로서니코틴아미드 피리딘우레아 | |
JP2004519503A (ja) | ファルネシルトランスフェラーゼ阻害剤 | |
CN115141197A (zh) | 一种3-芳杂环取代苯基衍生物及其制备方法与用途 | |
KR102258267B1 (ko) | TGase 2 억제제로서의 퀴놀린-5,8-디온 유도체 및 이를 포함하는 약제학적 조성물 | |
KR102377102B1 (ko) | TGase 2 억제제로서의 퀴놀린-5,8-디온 유도체의 제조 방법 | |
EP1403270A1 (en) | Pde iv inhibitors | |
CA2236851C (en) | Substituted vinylpyridine derivatives and drugs containing the same | |
NZ732796A (en) | Benzazepine dicarboxamide compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97191492.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2236851 Country of ref document: CA Ref document number: 2236851 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997940447 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980703387 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09068986 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1997940447 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980703387 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997940447 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019980703387 Country of ref document: KR |